Please login to the form below

systemic lupus erythematosus

This page shows the latest systemic lupus erythematosus news and features for those working in and with pharma, biotech and healthcare.

Merck to acquire Pandion Therapeutics for $1.85bn

of systemic lupus erythematosus and ulcerative colitis. ... In addition, Amgen is testing its own IL-2 candidate – AMG-592 – in patients with systemic lupus erythematosus and chronic graft-versus-host disease.

Latest news

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Elsewhere in its pipeline, Viela has a number of candidates in ongoing or planned phase 1/2 development – including VIB4920 for Sjögren’s syndrome, VIB7734 for systemic lupus erythematosus (SLE) and
Bayer signs €250m pact with India’s Curadev for STING drugs

in infancy (SAVI) and a subset of systemic lupus erythematosus (SLE).
Biogen scores mid-stage trial win for lupus drug BIIB059

Last approved treatment for Lupus was GSK's Benlysta in 2011. Biogen’s experimental drug for systemic lupus erythematosus (SLE) has hit the mark in a phase 2 trial, adding to ... BIIB059 hit all its objectives in the LILAC study, including a
Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Will now decide whether to file treatment for approval. A year ago, prospects for AstraZeneca’s systemic lupus erythematosus treatment anifrolumab were being written off. ... Lupus is a disease in which the immune system attacks normal cells and tissues
New data backs Merck’s segue into MS with BTK inhibitor

That mechanism also forms the basis of Merck’s testing of evobrutinib in rheumatoid arthritis and systemic lupus erythematosus (SLE), also at the phase 2 stage.

More from news
Approximately 2 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Rethinking trials: the pros and cons of protocol amendments

A protocol change can work wonders – just ask AstraZeneca. In August, AstraZeneca’s systemic lupus erythematosus candidate anifrolumab achieved the primary efficacy endpoint in an amended trial called Tulip-2. ... Systemic lupus erythematosus is a
Pharma deals during September 2012

In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Santhera CEO Klaus Schollmeier joins SuppreMol

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Clinical trials and the diversity principle

Examples abound, but systemic lupus erythematosus (SLE) – a disease for which there has only been one new drug approval since 1955 – is a notable case in point: while Black people account ... COVID has been like a magnifying glass, revealing systemic
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping

systemic lupus erythematosus (SLE).

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Content Editor - Biotechnology: Salary TBC

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Account Management: Competitive Salary Offered

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...